- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01401543
A Bioavailability Study of LY2452473 and Tadalafil
LY2452473 Formulation Exploratory Bioavailability Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overtly healthy male, as determined by medical history and physical examination
- Are between a body mass index of 18.5 and 30 kilograms per meter squared (kg/m²), inclusive at screening
- Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Normal blood pressure and heart rate (HR; sitting) as determined by the investigator
- Have venous access sufficient to allow blood sampling
- Are reliable and willing to make themselves available for the duration of the study, and will abide by the research unit policies and procedures and study restrictions
- Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
- Men must agree to use a reliable method of birth control (for example, vasectomy, condom with contraceptive foam, abstinence, or female partner's use of oral contraceptives or Norplant®; a reliable barrier method of birth control [diaphragm with contraceptive jelly]; or intrauterine device), during the study and for 1 month following the last dose of study drug
Exclusion Criteria:
- Have known allergies to LY2452473, tadalafil, or related compounds
- History of severe allergies or multiple adverse drug reactions
- Have a history or presence of cardiovascular, respiratory, hepatic (including history of cholecystectomy), renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Any abnormality in the 12-lead electrocardiogram (ECG) that in the opinion of the investigator places the subject at an unacceptable risk for study participation
- Show evidence of significant active neuropsychiatric disease
- History of significant retinal pathology
- Have a history of glaucoma
- Have a history of unexplained syncope episodes
- Show evidence of hepatitis C and/or positive hepatitis C antibody
- Show evidence of hepatitis B and/or positive hepatitis B surface antigen
- Show evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies
- Intended use of over-the-counter or herbal remedies within 7 days prior to dosing or during the study
- Intended use of prescription medication within 14 days prior to dosing or during the study
- Are not willing to refrain from consumption of any food, or drink any beverage containing grapefruit, pomelo, or starfruit for at least 2 weeks prior to the start of the study until its conclusion
- Heavy caffeine drinkers defined by a regular intake of more than 5 cups of coffee (or equivalent in xanthine-containing beverages) per day or subjects who have not had consistent daily caffeine consumption for 1 month prior to study entry or subjects not willing to maintain consistent caffeine consumption during the study
- Use of drugs of abuse, as evidenced by history, and/or positive findings on urinary drug screening
- Have an average weekly alcohol intake that exceeds 14 units per week or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 ounces [oz] or 360 milliliters (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
- Is currently a smoker or uses tobacco products on a regular basis and has not had consistent daily tobacco use for 1 month prior to study entry or subjects not willing to maintain consistent tobacco use during the study
- Have a history of blood donation of 1 unit (approximately 450 mL) or more in the last 3 months prior to study entry
- Have previously completed or withdrawn from this study or any other study investigating LY2452473
- Within 30 days of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication
- Deemed unsuitable by the investigator for any other reason
- Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 5 mg LY2452473 + 5 mg Tadalafil
5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only.
There will be a washout period of at least 7 days between doses of study drug.
|
Administered orally
Other Names:
Administered orally
|
Experimental: LY900010 (particle size #1)
Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value. |
Administered orally
|
Experimental: LY900010 (particle size #2)
Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value. |
Administered orally
|
Experimental: LY900010 (particle size #3)
Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug. d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value. |
Administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2452473
Time Frame: Predose up to 96 hours postdose for each of the 4 treatment periods
|
Predose up to 96 hours postdose for each of the 4 treatment periods
|
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2452473
Time Frame: Predose up to 96 hours postdose for each of the 4 treatment periods
|
Predose up to 96 hours postdose for each of the 4 treatment periods
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: AUC(0-∞) of Tadalafil
Time Frame: Predose up to 96 hours postdose for each of the 4 treatment periods
|
Predose up to 96 hours postdose for each of the 4 treatment periods
|
Pharmacokinetics: Cmax of Tadalafil
Time Frame: Predose up to 96 hours postdose for each of the 4 treatment periods
|
Predose up to 96 hours postdose for each of the 4 treatment periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13326
- I4K-MC-GPEA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
Clinical Trials on Tadalafil
-
Institute for the Study of Urological Diseases,...RecruitingErectile DysfunctionGreece
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedBenign Prostatic HyperplasiaJapan
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownObesity and Erectile DysfuntionMexico
-
Futura Medical Developments Ltd.CompletedErectile DysfunctionUnited States, Bulgaria, Georgia, Poland
-
Saint Petersburg State University, RussiaRecruitingErectile DysfunctionRussian Federation
-
University of PernambucoUnknown
-
Cairo UniversityUnknownErectile DysfunctionEgypt
-
Cedars-Sinai Medical CenterCompleted
-
Mark FeinglosEli Lilly and Company; Duke UniversityWithdrawnNausea | Vomiting | Gastroparesis | Diabetic GastroparesisUnited States